Skip to content
Science
Our Science
Autoimmunity
P140
Type M & Diagnostic
Type 1 Diabetes
Kapiglucagon
Anti-infectives
BioAMB
BioCIN
Pipeline
Company
Mission
About Us
Our Team
ImmuPharma Biotech
Investors
Investors
AIM Rule 26 Information
Regulatory News
Corporate Governance
Board of Directors
Annual Reports
Advisers
Email Alert
Updates
Announcements
Interviews
In the Media
Contact
TR1 from Lanstead Capital – Major interest in shares
Aug 20, 2025
Standard form for notification of major holdings
To view
click here
←
Previous:
INTERIM RESULTS for the six months ended 30 June 2025
Next:
ImmuPharma Files Groundbreaking New Patent Application for P140: First-in-Class ‘Immunormalizer’ for Precision Diagnosis and Treatment of Autoimmune Diseases
→
